Heron Therapeutics (HRTX) Interest Expenses (2011 - 2026)
Heron Therapeutics' (HRTX) quarterly Interest Expenses came in at $2.6 million in Q1 2026, up 228.38% YoY from $800000.0 in Q1 2025, and down 63.54% on a QoQ basis from $7.2 million in Q4 2025.
Heron Therapeutics (HRTX) Interest Expenses (2011 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 16 years of Interest Expenses data on file, last reported at $2.6 million in Q1 2026.
- Quarterly Interest Expenses rose 228.38% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.4 million (up 86.43% YoY) and the FY2025 annual result came in at $415.0 million, up 6779.96% from the prior year.
- Interest Expenses fell to $2.6 million in Q1 2026, from $7.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $7.2 million in Q4 2025 to a low of $500000.0 in Q3 2023.
- A 5-year average of $1.7 million and a median of $800000.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses dropped 28.57% — and 2025, when it soared 287.5%.
- Tracing HRTX's Interest Expenses over 5 years: stood at $1.3 million in 2022, then jumped by 31.28% to $1.8 million in 2023, then soared by 105.08% to $3.6 million in 2024, then jumped by 98.38% to $7.2 million in 2025, then plunged by 63.54% to $2.6 million in 2026.
- The last three Interest Expenses figures came in at $2.6 million (Q1 2026), $7.2 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.98 Mn |
| Jun 30, 2026 | 5.98 Mn |
| Mar 31, 2026 | 2.63 Mn |
| Mar 31, 2026 | 2.63 Mn |
| Dec 31, 2025 | 7.21 Mn |
| Dec 31, 2025 | 7.21 Mn |
| Sep 30, 2025 | 3.10 Mn |
| Sep 30, 2025 | 3.10 Mn |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 3.63 Mn |
| Dec 31, 2024 | 3.63 Mn |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 800,000.00 |
| Mar 31, 2024 | 800,000.00 |